Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
HBM HOLDINGSHBM HOLDINGS(HK:02142) Prnewswire·2026-03-23 03:14

Group 1 - Harbour BioMed is a global biopharmaceutical company focused on the discovery and development of novel antibodies [1] - The company is listed on the Hong Kong Stock Exchange under the ticker 02142 [1]

Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody - Reportify